Inotek Pharmaceuticals Corporation
Pharmaceuticals - Lexington, Massachusetts, United States
Inotek Pharmaceuticals Corporation Employees
Chaim Brickman
Senior Medical Director for Clinical Development and Pharmacovigilance
Inotek Pharmaceuticals Corporation Senior Management
Inotek Pharmaceuticals Corporation Details
Inotek Pharmaceuticals is a clinical-stage, publicly traded, biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat glaucoma and other serious diseases of the eye. Our common stock is listed on the NASDAQ Global Market under the symbol "ITEK." Glaucoma is a disease of the eye that is typically characterized by structural evidence of optic nerve damage, vision loss and consistently elevated intraocular pressure, or IOP. Our lead product candidate, trabodenoson, is a first-in-class selective adenosine mimetic. Trabodenoson has completed Phase 2 clinical development in primary open-angle glaucoma (POAG) and ocular hypertensive (OHT) patients and is ready for Phase 3. Trabodenoson, if ultimately approved by regulatory agencies, will be a valuable, innovative product that ophthalmologists can use alone or in combination with other approved medicines for glaucoma, and would also be a new treatment option for those patients who are refractory to current drug therapies. Inotek, in addition to having built a potential first-in-class ophthalmic product candidate in trabodenoson, has an experienced management team with a track record of multiple successful NDA approvals and successful product launches. Inotek intends to advance its programs through regulatory approval and to market its ophthalmology products, a specialty area, with a relatively small and focused sales and marketing team. The Company is based in Lexington, MA.
Inotek Pharmaceuticals Corporation Technologies
Load Balancers
Nginx
CMS
WordPress.org
Fonts
Google Font API
Other
Mobile Friendly